Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. DHR
DHR logo

DHR Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
197.880
Open
197.420
VWAP
194.74
Vol
3.25M
Mkt Cap
137.44B
Low
192.140
Amount
632.68M
EV/EBITDA(TTM)
19.23
Total Shares
707.77M
EV
149.83B
EV/OCF(TTM)
23.27
P/S(TTM)
5.58
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services. The Company also provides pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings.
Show More

Events Timeline

(ET)
2026-06-22
08:30:00
Danaher’s Masimo Receives FDA Clearance for OIRD Detection
select

News

PRnewswire
7.0
07-03PRnewswire
Halper Sadeh LLC Investigates Danaher Corporation Executives' Fiduciary Duties
  • Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether Danaher Corporation executives breached their fiduciary duties to shareholders, which could lead to corporate governance reforms and fund returns, thereby enhancing shareholder rights.
  • Legal Fee Arrangement: The firm operates on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal expenses, a strategy designed to reduce the financial burden on shareholders and encourage participation in legal actions.
  • Importance of Shareholder Participation: Involvement from shareholders can improve company policies and oversight mechanisms, enhancing transparency and accountability, which in turn boosts management efficiency and shareholder value, demonstrating the power of collective action.
  • Global Investor Representation: Halper Sadeh LLC represents investors worldwide affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, showcasing their expertise in protecting investor rights.
PRnewswire
8.5
06-29PRnewswire
Danaher Foundation Commits $1 Million to Combat Ebola Outbreak
  • Emergency Funding Support: The Danaher Foundation has announced a $1 million commitment to support the Ebola outbreak response in the Democratic Republic of Congo and Uganda, aiming to rapidly address urgent needs through partnerships with Save the Children, the International Rescue Committee, and World Food Program USA.
  • Collaborative Response Efforts: The funding will be distributed among the three organizations to enable flexible responses to critical needs such as infection prevention, hygiene support, and emergency food assistance, ensuring resources reach the most affected communities quickly as the situation evolves.
  • Children's Health Crisis: According to the World Health Organization, over 1,000 cases of Ebola have been confirmed in the DRC, with children being particularly vulnerable and more than twice as likely to die after infection, highlighting the urgent need for access to basic healthcare and protection.
  • Global Health Challenge: The outbreak has been declared a Public Health Emergency of International Concern by the WHO, reflecting the severe consequences of long-term underinvestment in health services and recent global funding cuts in a fragile humanitarian environment.
Newsfilter
8.5
06-29Newsfilter
Danaher Foundation Commits $1 Million to Combat Ebola Outbreak
  • Emergency Funding Support: The Danaher Foundation has announced a $1 million commitment to support the Ebola outbreak response in the Democratic Republic of Congo and Uganda, aiming to rapidly address urgent needs through partnerships with Save the Children, the International Rescue Committee, and World Food Program USA.
  • Collaborative Response Efforts: The funding will be distributed among the three organizations to enable flexible responses to critical needs such as infection prevention, hygiene support, and community health services, thereby directly saving lives and mitigating the impact of the outbreak.
  • Children's Health Crisis: According to the World Health Organization, over 1,000 cases of Ebola have been confirmed in the DRC, with children being particularly vulnerable and more than twice as likely to die after infection, highlighting the urgent need for basic healthcare and protection.
  • Global Health Challenge: The Ebola outbreak has been declared a Public Health Emergency of International Concern by the WHO, marking it as the largest known Bundibugyo virus outbreak in history, underscoring the severe consequences of global underinvestment in health services.
Yahoo Finance
4.0
06-28Yahoo Finance
Danaher Corporation Rated as Top Non-Tech Stock by Analysts
  • FDA 510(k) Clearance: Masimo announced FDA 510(k) clearance for its Radius VSM® wearable continuous patient monitor, which now includes an opioid-induced respiratory depression detection capability that utilizes advanced pattern recognition to analyze continuous physiological data, enabling clinicians to identify early signs of respiratory compromise in patients receiving opioid therapy, thereby enhancing patient safety and monitoring efficiency.
  • Analyst Rating Changes: Piper Sandler has initiated coverage of Danaher Corporation (DHR) while expressing caution regarding its future growth catalysts, noting that the current growth outlook is similar to past performance and that Thermo Fisher appears slightly cheaper on a P/E basis, indicating market divergence in expectations for Danaher's future performance.
  • Market Positioning Analysis: Danaher’s design, manufacturing, and marketing of professional, medical, industrial, and commercial products and services position it as a significant diagnostics stock, although analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, reflecting a diverse perspective on investment opportunities in the current market.
  • Investment Potential Assessment: While Danaher is viewed as a potentially strong investment, analysts express insufficient confidence in its future growth, suggesting that in the current market environment, some AI stocks may be more attractive, prompting investors to carefully consider the balance of risk and reward in their selections.
Fool
8.5
06-24Fool
Danaher's Masimo Acquisition Raises Concerns Amid Growth Potential
  • Acquisition Potential: Danaher's $9.9 billion acquisition of Masimo raises patent dispute concerns but is expected to add $0.15 to $0.20 to adjusted EPS in the first year, scaling to $0.70 by year five, indicating significant future growth potential.
  • First Quarter Recovery: In Q1, Danaher reported revenue of $5.95 billion, a 3% year-over-year increase, with EPS at $1.45, up 9.8%, demonstrating financial resilience despite a 22% stock price decline this year.
  • Significant Order Growth: The company noted a 30% year-over-year increase in equipment orders, signaling the start of a multi-year manufacturing investment cycle, bolstered by reshoring trends and renewed interest in the life sciences sector.
  • Low Market Valuation: Despite execution risks, Danaher's stock trades at just over 20 times forward earnings, significantly below its typical valuation over the past decade, suggesting that if management successfully integrates Masimo, the current stock price may be undervalued.
Yahoo Finance
8.5
06-24Yahoo Finance
Danaher's Masimo Acquisition Raises Concerns Amid Stock Decline
  • Acquisition Impact: Danaher's $9.9 billion acquisition of Masimo is expected to boost adjusted EPS by $0.15 to $0.20 in the first year, yet it raises concerns over patent disputes with Apple and increased debt levels.
  • Financial Performance: In Q1 2023, Danaher reported revenues of $5.95 billion, a 3% year-over-year increase, with EPS at $1.45, reflecting a 9.8% growth, demonstrating resilience amid challenges.
  • Market Dynamics: The U.S. pharma and life sciences sector saw M&A activity exceed $65 billion in Q1 2026, nearly doubling the previous year's total, indicating large pharmaceutical companies are seeking acquisitions to enhance their pipelines, which could benefit Danaher's equipment sales.
  • Future Outlook: Despite the execution risks of integrating Masimo, Danaher raised its 2026 EPS guidance to a range of $8.35 to $8.55, indicating confidence in future growth, although the market remains cautious about the stock's rebound potential.
Wall Street analysts forecast DHR stock price to rise
18 Analyst Rating
Wall Street analysts forecast DHR stock price to rise
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
240.00
Averages
266.18
High
310.00
Current: 0.000
sliders
Low
240.00
Averages
266.18
High
310.00
Evercore ISI
Vijay Kumar
Outperform
to
Outperform
downgrade
$232 -> $230
AI Analysis
2026-07-06
New
Reason
Evercore ISI
Vijay Kumar
Price Target
$232 -> $230
AI Analysis
2026-07-06
New
downgrade
Outperform
to
Outperform
Reason
Evercore ISI analyst Vijay Kumar lowered the firm's price target on Danaher to $230 from $232 and keeps an Outperform rating on the shares. The firm's Q2 preview for MedTech, Life Sciences Tools, and Diagnostics highlights generally healthy procedure volumes and capital expenditure trends across the sector, the analyst tells investors in a research note.
Piper Sandler
Neutral
initiated
$200
2026-06-11
Reason
Piper Sandler
Price Target
$200
2026-06-11
initiated
Neutral
Reason
Piper Sandler initiated coverage of Danaher with a Neutral rating and $200 price target. The firm launched coverage of the life science tools sector with a \"feet in the shallow end of the pool\" approach. Piper only recommends buying Twist Bioscience for its growing exposure to next generation drug discovery and development. Headwinds for the group faces from biotech and academic spending as well as China exposure will likely improve near term, the analyst tells investors in a research note. However, Piper wants to see some of the next big growth drivers materialize before recommending more of the stocks. Investors \"can buy multi-year growth compounding stocks early, middle, and late into their growth cycles but would simply prefer to wait out a couple quarters for the sector to perform like it did pre-Covid,\" the firm contends.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for DHR
Unlock Now

Valuation Metrics

The current forward P/E ratio for Danaher Corp (DHR.N) is 23.42, compared to its 5-year average forward P/E of 28.45. For a more detailed relative valuation and DCF analysis to assess Danaher Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
28.45
Current PE
23.42
Overvalued PE
32.02
Undervalued PE
24.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
22.42
Current EV/EBITDA
17.26
Overvalued EV/EBITDA
25.11
Undervalued EV/EBITDA
19.72

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
6.58
Current PS
4.96
Overvalued PS
7.48
Undervalued PS
5.69

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

Bullish price predictions
Intellectia · 11 candidates
Region: USThemes: Aerospace & Defense, Robotics, The Internet of Things, Space Economy, Renewable Energy, IndustrialRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200One Day Rise Prob: >= 50One Day Predict Return: >= 0.0%One Week Rise Prob: >= 50One Week Predict Return: >= 0.0%Macd: bullish
Ticker
Name
Market Cap$
top bottom
PCAR logo
PCAR
Paccar Inc
59.08B
DHR logo
DHR
Danaher Corp
122.54B
BEP logo
BEP
Brookfield Renewable Partners LP
11.08B
GD logo
GD
General Dynamics Corp
92.67B
LDOS logo
LDOS
Leidos Holdings Inc
16.43B
BLX logo
BLX
Banco Latinoamericano de Comercio Exterior SA
2.11B
what are the Helium stocks available
Intellectia · 27 candidates
Themes: Industrial
Ticker
Name
Market Cap$
top bottom
CAT logo
CAT
Caterpillar Inc
413.36B
GE logo
GE
General Electric Co
310.03B
BA logo
BA
Boeing Co
187.11B
ETN logo
ETN
Eaton Corporation PLC
155.91B
DE logo
DE
Deere & Co
155.27B
HON logo
HON
Honeywell International Inc
135.04B
option with low spread for today
Intellectia · 192 candidates
Price: $20.00 - $500.00Market Cap Category: large, midRelative Vol: >= 1Is Optionable: TrueOption Iv Rank: 20 - 60Is Index Component: GSPC, NDX, DJI, RUT
Ticker
Name
Market Cap$
top bottom
NEE logo
NEE
Nextera Energy Inc
194.60B
DIS logo
DIS
Walt Disney Co
188.69B
BA logo
BA
Boeing Co
182.12B
ANET logo
ANET
Arista Networks Inc
178.49B
TMO logo
TMO
Thermo Fisher Scientific Inc
176.32B
T logo
T
AT&T Inc
175.52B
USA rare earth
Intellectia · 57 candidates
Market Cap: >= 0Region: USPrice: >= $0.00Themes: Gold Mining and Precious Metals, Uranium, Mining, IndustrialList Exchange: XNYS, XNAS, XASEIs Optionable: TrueMonthly Average Dollar Volume: >= 0
Ticker
Name
Market Cap$
top bottom
CAT logo
CAT
Caterpillar Inc
376.91B
GE logo
GE
General Electric Co
295.86B
BHP logo
BHP
BHP Group Ltd
195.76B
BA logo
BA
Boeing Co
176.67B
ETN logo
ETN
Eaton Corporation PLC
159.37B
RIO logo
RIO
Rio Tinto PLC
156.91B
stocks with over 80% upside
Intellectia · 534 candidates
Market Cap: >= 1000.00MRegion: USAnalyst Consensus: Strong Buy, Moderate BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMonthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.86T
MSFT logo
MSFT
Microsoft Corp
3.15T
V logo
V
Visa Inc
590.75B
ORCL logo
ORCL
Oracle Corp
521.05B
BABA logo
BABA
Alibaba Group Holding Ltd
323.80B
TMUS logo
TMUS
T-Mobile US Inc
215.29B
what stocks will thrive this week
Intellectia · 121 candidates
Region: USAnalyst Consensus: Strong Buy, Moderate Buy, Hold, Moderate Sell, Strong SellList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePrice, AbovePrice, BelowPrice, MoreBelowPriceMoving Average Relationship: PriceAboveMA5, PriceAboveMA20, PriceAboveMA200, PriceCrossAboveMA5, PriceCrossDownMA5Week Price Change Pct: $-100.00 - $100.00Month Price Change Pct: $-100.00 - $100.00Is Optionable: TrueOption Sentiments: Bullish, Neutral, BearishOne Week Rise Prob: 0 - 100One Week Predict Return: -100.0% - 100.0%Macd: positive, negative, bearish, bullish
Ticker
Name
Market Cap$
top bottom
TSLA logo
TSLA
Tesla Inc
1.50T
PG logo
PG
Procter & Gamble Co
343.34B
LRCX logo
LRCX
Lam Research Corp
334.17B
GE logo
GE
General Electric Co
317.76B
UNH logo
UNH
UnitedHealth Group Inc
294.66B
PM logo
PM
Philip Morris International Inc
245.92B
which stocks have only buy ratings?
Intellectia · 34 candidates
Market Cap: >= 20.00BAnalyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceIs Index Component: GSPC, NDX
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.46T
MSFT logo
MSFT
Microsoft Corp
3.05T
AVGO logo
AVGO
Broadcom Inc
1.58T
AMD logo
AMD
Advanced Micro Devices Inc
325.19B
UNH logo
UNH
UnitedHealth Group Inc
262.11B
ABT logo
ABT
Abbott Laboratories
192.95B
stocks that predict to rise in one week
Intellectia · 39 candidates
Market Cap: >= 5.00BPrice: $10.00 - $250.00One Week Rise Prob: >= 72One Week Predict Return: >= 3.0%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
CVE logo
CVE
Cenovus Energy Inc
42.47B
SCHW logo
SCHW
Charles Schwab Corp
164.81B
NI logo
NI
NiSource Inc
22.11B
ATO logo
ATO
Atmos Energy Corp
30.06B
CIGI logo
CIGI
Colliers International Group Inc
5.69B
RGEN logo
RGEN
Repligen Corp
7.62B
who has earnings today’s
Intellectia · 83 candidates
List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
MSFT logo
MSFT
Microsoft Corp
3.52T
META logo
META
Meta Platforms Inc
1.68T
TSLA logo
TSLA
Tesla Inc
1.44T
ASML logo
ASML
ASML Holding NV
567.84B
LRCX logo
LRCX
Lam Research Corp
281.28B
IBM logo
IBM
International Business Machines Corp
274.65B
Which stocks are making 3 months highs?
Intellectia · 96 candidates
Market Cap: >= 10.00BMarket Cap Category: largeNew High Low: 20_HighQuarter Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
BA logo
BA
Boeing Co
190.08B
AMGN logo
AMGN
Amgen Inc
185.02B
DHR logo
DHR
Danaher Corp
170.97B
GILD logo
GILD
Gilead Sciences Inc
160.18B
Low logo
Low
Lowe's Companies Inc
155.45B
PFE logo
PFE
Pfizer Inc
147.20B

Whales Holding DHR

B
Bluebox Asset Management Uk Ltd.
Holding
DHR
+42.49%
3M Return
P
Pallas Capital Advisors LLC
Holding
DHR
+27.63%
3M Return
S
Suvretta Capital Management, LLC
Holding
DHR
+21.79%
3M Return
B
Bellevue Asset Management AG
Holding
DHR
+19.99%
3M Return
W
Walleye Capital LLC
Holding
DHR
+19.51%
3M Return
B
Beacon Investment Advisory Services, Inc.
Holding
DHR
+17.67%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Danaher Corp (DHR) stock price today?

The current price of DHR is 194.19 USD — it has increased 0.29

What is Danaher Corp (DHR)'s business?

Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services. The Company also provides pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings.

What is the price predicton of DHR Stock?

Wall Street analysts forecast DHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DHR is266.18 USD with a low forecast of 240.00 USD and a high forecast of 310.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Danaher Corp (DHR)'s revenue for the last quarter?

Danaher Corp revenue for the last quarter amounts to 5.95B USD, increased 3.66

What is Danaher Corp (DHR)'s earnings per share (EPS) for the last quarter?

Danaher Corp. EPS for the last quarter amounts to 1.45 USD, increased 9.85

How many employees does Danaher Corp (DHR). have?

Danaher Corp (DHR) has 58000 emplpoyees as of July 08 2026.

What is Danaher Corp (DHR) market cap?

Today DHR has the market capitalization of 137.44B USD.